FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.
What happened
FDA inspected the Glenmark Pharmaceuticals Limited drug manufacturing facility in Pithampur, India, from February 3 to 14, 2025. FDA found inadequate investigations of repeated dissolution failures for potassium chloride extended-release capsules and another capsule product, a backlog of overdue stability testing, and test methods that were not validated or verified. The letter also cites similar violations at other Glenmark sites.
What FDA found
Glenmark did not thoroughly investigate repeated dissolution failures for potassium chloride extended-release capsules or another capsule product.
21 CFR 211.192Glenmark did not complete stability testing on time and did not adequately assess the backlog's risk to patients.
21 CFR 211.166(a)Glenmark used test methods for incoming active ingredients and drug products that had not been validated or verified.
21 CFR 211.160(b)FDA cited similar manufacturing violations at other Glenmark sites, showing inadequate management oversight.
What FDA wants
FDA asks Glenmark to correct the violations promptly, provide the requested investigations, assessments and corrective action plans, and respond in writing within 15 working days. FDA also recommends engaging a consultant qualified in current good manufacturing practice (CGMP) and says to notify FDA before resuming manufacturing for the U.S. market.
Who should pay attention
- companies that buy or distribute Glenmark drug products
- quality teams managing supplier oversight and stability programs
- drugmakers with multi-site manufacturing networks
This is a summary. Read the original letter on fda.gov.